Royal Bio-Pharmaceutical

Royal Bio-Pharmaceutical, officially known as Shanghai Royal Bio-Pharmaceutical Co., Ltd., is a biopharmaceutical company headquartered in Shanghai, China, specializing in the production of recombinant human proteins. Founded in 1994, the company has established itself as a key player in the Chinese biologics market, focusing on therapies for hematological and oncological conditions. Its core product line includes recombinant human erythropoietin (rhEPO) for treating anemia and recombinant human granulocyte colony-stimulating factor (rhG-CSF) for chemotherapy-induced neutropenia. Since its integration into Shanghai Pharmaceuticals Holding Co., Ltd. (SPH), Royal Bio-Pharmaceutical has benefited from extensive R&D resources and a broad national distribution network. The company also manufactures and markets other cytokine-based therapies, including Interleukin-2 and Interleukin-11, maintaining a strong presence in hospital-based specialty therapeutics.